SCHEMBL5472385

SCHEMBL5472385

COc1cccc(C=C2C(=O)Nc3ccccc32)c1O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.78
DHFR P00374 1/20 0.67
PLK4 O00444 2/20 0.63
PLK1 P53350 2/20 0.63
MDM2 Q00987 1/20 0.62
MAP3K7 O43318 1/20 0.62
TAB1 Q15750 1/20 0.62
CCNE1 P24864 1/20 0.60
CDK2 P24941 1/20 0.60
CSNK1D P48730 3/20 0.58
CSNK1A1 P48729 2/20 0.58
CSNK1E P49674 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
GMNN O75496 1/20 0.58
ALDH1A1 P00352 1/20 0.58
LMNA P02545 1/20 0.58
TP53 P04637 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
MAPT P10636 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5472383 1.00 NPC1 (0.78) NPC1DHFRPLK4PLK1MDM2
SCHEMBL16442345 0.88 NPC1 (1.00) NPC1DHFRPLK4PLK1MDM2
SCHEMBL5469690 0.88 NPC1 (1.00) NPC1DHFRPLK4PLK1MDM2
SCHEMBL5469692 0.88 NPC1 (1.00) NPC1DHFRPLK4PLK1MDM2
SCHEMBL29367529 0.88 NPC1 (1.00) NPC1DHFRPLK4PLK1MDM2
SCHEMBL16442336 0.86 NPC1 (0.62) NPC1DHFRPLK4PLK1MDM2
SCHEMBL5477376 0.86 NPC1 (0.80) NPC1DHFRPLK4PLK1MDM2
SCHEMBL5477373 0.86 NPC1 (0.80) NPC1DHFRPLK4PLK1MDM2
SCHEMBL5464433 0.82 CSNK1D (0.78) NPC1DHFRPLK4PLK1MDM2
SCHEMBL13044217 0.82 MEN1 (0.77) NPC1L3MBTL1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 NPC1 4188/4885DHFR 3147/4885PLK4 3502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.